ストックスクリーナーアプリを入手
3.67
6.14%
-0.24
アフターアワーズ：
3.59
-0.08
-2.18%
Scynexis Inc (SCYX) 最新ニュース
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Nigeria
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com
SCYNEXIS (SCYX) Completes Phase 1 Trial for SCY-770 Targeting AD - GuruFocus
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Canada
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative
An experimental kidney disease drug was well tolerated in 25 healthy adults - Stock Titan
SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions - Simply Wall Street
Stock splits calendar for: - Yahoo Finance UK
Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 - AllSci
Scynexis wins BARDA contract worth up to $214 million for antifungal SCY-247 - The Pharma Letter
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline - TipRanks
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Scynexis stock surges on $214M BARDA contract for SCY-247 - Yahoo Finance
Scynexis stock surges on $214M BARDA contract for SCY-247 - Investing.com
SCYX Stock Draws Trader Focus As New CFO And ADPKD Pivot Take Shape - timothysykes.com
SCYX Stock Draws Traders As Leadership And Kidney Pivot Advance - StocksToTrade
SCYNEXIS Wins BARDA Contract Worth Up to $214 Million for SCY-247 - citybiz
SCYNEXIS secures BARDA contract for antifungal development - Investing.com
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract - Yahoo Finance
Why is Scynexis stock surging today? By Investing.com - Investing.com South Africa
Why is Scynexis stock surging today? By Investing.com - Investing.com Canada
Why is Scynexis stock surging today? - Investing.com
SCYNEXIS secures BARDA contract for antifungal development By Investing.com - Investing.com India
A U.S. health agency could provide up to about $214 million to develop an antifungal treatment if all options are exercised. - Stock Titan
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch - TradingView
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - manilatimes.net
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - marketscreener.com
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - Stock Titan
Press Release: SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to Its Board of Directors - Moomoo
SCYXPhase II ADPKD Catalyst Will Define Long-Term Potential For This Orphan Kidney Therapy - Simply Wall Street
SCYNEXIS (Nasdaq:SCYX)Stock Analysis - Simply Wall Street
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com Nigeria
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com India
2.08%
1.49%
大文字化:
|
ボリューム (24 時間):